Can you provide detailed protocols for the clonidine suppression test, plasma chromogranin A measurement, and 18F‑fluorodopamine (18F‑FDA) PET imaging, including radiopharmaceutical preparation?

18F-Fluorodopamine PET Protocol for Pheochromocytoma/Paraganglioma

For 18F-fluorodopamine (18F-FDA) PET imaging in pheochromocytoma/paraganglioma, the tracer is synthesized via direct radiofluorination of dopamine with [18F]F2, achieving specific activity of 10 ± 1.5 Ci/mmol, and demonstrates superior sensitivity for detecting primary tumors (except head/neck locations) compared to other functional imaging modalities.

18F-Fluorodopamine (18F-FDA) PET Imaging

Radiopharmaceutical Preparation

Synthesis Method:

• 18F-FDA is produced by direct fluorination of dopamine using [18F]F2 (from 18O(p,n)18F nuclear reaction) 1
• Reaction occurs in anhydrous hydrogen fluoride containing boron trifluoride at -65°C
• Reverse-phase HPLC separates [18F]6-FDA from 18F-labeled 2- and 5-FDA isomers
• Radiochemical yield: 10 ± 2% relative to [18F]F2 at end of 120-minute synthesis 1
• Specific activity: 10 ± 1.5 Ci/mmol at end of synthesis 1

Clinical Dosing:

• Administered dose: 1-4 mCi (37-148 MBq) via 3-minute intravenous infusion 2
• For a 50-kg patient receiving 5 mCi, the dopamine dose (0.5-0.7 μg/kg/min) is substantially lower than therapeutic dopamine doses (2-10 μg/kg/min) 1

Mechanism and Pharmacokinetics

18F-FDA is taken up by sympathetic nerve terminals via the norepinephrine transporter (NET), then translocated into storage vesicles where it undergoes beta-hydroxylation to 6-[18F]fluoronorepinephrine 2. This mechanism allows visualization of catecholamine-producing tumors.

Metabolic Profile:

• By 24 hours post-injection, the main urinary metabolite is 6F-vanillylmandelic acid 2
• Urinary elimination: 50% within 1 hour, remainder within 12 hours (similar to 18F-FDOPA pathway) 3

Imaging Protocol

Patient Preparation:

• Minimal hemodynamic effects expected (slight, transient blood pressure increase) 2
• No specific fasting requirements documented for 18F-FDA (unlike 18F-FDOPA which requires 4-hour fast)

Image Acquisition:

• Timing not explicitly specified in guidelines, but cardiac imaging studies used immediate post-infusion scanning 2
• Field of view: Base of skull to mid-thighs or whole-body depending on clinical indication

Radiation Dosimetry:

• Target organ: Urinary bladder wall
• Estimated absorbed dose: 0.8-1.0 rad/mCi (0.22-0.27 mGy/MBq) 2

Diagnostic Performance

Clinical Efficacy:

• Sensitivity: 100% (9/9) for surgically confirmed pheochromocytomas 4
• Specificity: 82% (9/11) in patients with normal plasma metanephrines 4
• All 8 patients with metastatic disease showed extra-adrenal sites of uptake 4
• Superior to other modalities for primary pheochromocytomas except head/neck paragangliomas 5

Important Caveat: 18F-FDA has limited availability and is only accessible at specialized centers 5. For most clinical settings, 18F-FDOPA remains the more practical alternative.

---

Clonidine Suppression Test (CST)

The clonidine suppression test reliably excludes false-positive normetanephrine elevations with 100% specificity and should be used when baseline plasma normetanephrine is elevated up to 1.7-fold above the upper reference limit in patients with suspected pheochromocytoma.

Protocol Details

Indications:

• Moderate elevations of plasma normetanephrine (NMN) 6
• Baseline NMN up to 1.7-fold above upper reference limit 7
• Not useful for isolated metanephrine (MN) elevations - sensitivity drops from 94% to 85% when including these cases 7

Procedure:

• Dose: 150 μg clonidine orally (based on pediatric case) 8 or standard adult dosing
• Measure plasma catecholamines (norepinephrine) and normetanephrine before and after administration
• In true pheochromocytoma: catecholamine levels remain elevated or increase 8
• In false-positive cases: catecholamine levels suppress normally 8

Interpretation:

• Positive test (suggests pheochromocytoma): Failure of normetanephrine to suppress 7
• Negative test (excludes pheochromocytoma): Normal suppression of normetanephrine 7
• Specificity: 100% for excluding false-positive NMN results 7
• Sensitivity: 94% when excluding isolated MN-secreting tumors 7

Clinical Context

In the prospective trial by Geroula et al., CST correctly identified all 7 patients (26.9%) with falsely elevated baseline NMN among 26 patients without pheochromocytoma 7. This makes CST particularly valuable in the differential diagnosis of borderline elevated plasma-free normetanephrine.

Drug Interactions: Clonidine has minimal effect on plasma chromogranin A levels, preserving the utility of this biomarker 9

---

Plasma Chromogranin A Measurement

Plasma chromogranin A demonstrates 83% sensitivity and 96% specificity for pheochromocytoma diagnosis, superior to plasma catecholamines in specificity, and correlates with tumor mass and overall catecholamine production.

Diagnostic Performance

Sensitivity and Specificity:

• Sensitivity: 83% (24/29 patients with pheochromocytoma) 9
• Specificity: 96% (86/90 reference subjects) - superior to plasma catecholamines 9
• Correctly identified all 5 patients in whom pheochromocytoma was ultimately ruled out 9

Reference Groups:

• Normotensive controls (n=49)
• Essential hypertension (n=28)
• Renovascular hypertension (n=5)
• Primary aldosteronism (n=3)

Clinical Correlations

Tumor Characteristics: Chromogranin A correlates with:

• Tumor mass 9
• Tumor chromogranin A content 9
• Tumor norepinephrine content 9
• Urinary vanillylmandelic acid excretion 9

Does NOT correlate with:

• Plasma or urinary catecholamines 9
• Blood pressure in pheochromocytoma patients 9

Important Considerations

Confounding Factors:

• Renal failure: Elevates chromogranin A independently of blood pressure 9
• Essential hypertension: Modest elevation possible, correlates with diastolic blood pressure 9
• However, these elevations do not impair diagnostic utility for pheochromocytoma 9

Drug Effects: Minimal interference from medications commonly used in pheochromocytoma diagnosis/treatment:

• Clonidine 9
• Metoprolol 9
• Phentolamine 9
• Tyramine 9

Tumor Biology: Within pheochromocytoma tissue, chromogranin A:

• Localizes to soluble core of chromaffin granules alongside catecholamines 9
• Accounts for 18 ± 5% of vesicle soluble protein 9
• Co-stored and co-released with catecholamines 9

Clinical Utility

Chromogranin A provides a useful adjunct to catecholamine measurements, offering superior specificity while maintaining comparable sensitivity. Its independence from commonly used medications and correlation with tumor burden make it particularly valuable for monitoring disease progression and treatment response 9.